Douglas Johnson
1 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Itacitinib for the Treatment Steroid Refractory Immune Related Adverse Events Arising From Immune Checkpoint Inhibitors (NCT05660421) | Douglas Johnson | 2023-03-03 |
Track Douglas Johnson automatically
Every clearance here is in the API, with alerts when new ones post.